References
Canadian Network for Mood and Anxiety Treatments (CANMAT) (1999) Guidelines for the diagnosis and pharmacological treatment of depression. Cameron McCleery Productions Ltd, Toronto, Canada
Chehil S, Devarajan S, Dursun SM (2000) Pharmacological strategies for refractory depression. Can Fam Phys (in press)
Cowen PJ (1998) Pharmacological management of treatment resistant depression. Adv Psychiatr Treat 4:320–327
Devarajan S, Dursun SM (2000) Citalopram plus reboxetine in treatment-resistant depression. Can J Psychiatry 45:489–490
Souery D, Amsterdam J, deMontigny C, Lecrubien Y, Montogemery S, Lipp O et al. (1999) Treatment resistant depression: methological overview and operational criteria. Eur Neuropsychiatr 9:83–91
O'Reardon JP, Amsterdam JD (1998) Treatment-resistant depression: progress and limitations. Psychiatr Ann 28:633–640
Whale R, Quested DJ, Laver D, Harrison PJ, Cowen PJ (2000) Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology 150:120–122
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dursun, S., Devarajan, S. Reboxetine plus citalopram for refractory depression not responding to venlafaxine: possible mechanisms. Psychopharmacology 153, 497–498 (2001). https://doi.org/10.1007/s002130000579
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s002130000579